Comment
doi: 10.1111/jth.14349.
Epub 2018 Dec 24.
Comparative analysis of marketed factor VIII products: reply
Affiliations
- PMID: 30489690
- PMCID: PMC6975161
- DOI: 10.1111/jth.14349
Item in Clipboard
Comment
Comparative analysis of marketed factor VIII products: reply
J Thromb Haemost.
2019 Jan.
No abstract available
Conflict of interest statement
This work was funded by Shire. All authors are employees of Shire.
Comment on
-
Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.J Thromb Haemost. 2018 Jun;16(6):1176-1181. doi: 10.1111/jth.14125. Epub 2018 May 11. J Thromb Haemost. 2018. PMID: 29665242
-
Comparative analysis of marketed factor VIII products: comment.J Thromb Haemost. 2019 Jan;17(1):232-233. doi: 10.1111/jth.14321. Epub 2018 Dec 24. J Thromb Haemost. 2019. PMID: 30376211 No abstract available.
Similar articles
-
Comparative analysis of marketed factor VIII products: comment.J Thromb Haemost. 2019 Jan;17(1):232-233. doi: 10.1111/jth.14321. Epub 2018 Dec 24. J Thromb Haemost. 2019. PMID: 30376211 No abstract available.
-
Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.J Thromb Haemost. 2018 Jun;16(6):1176-1181. doi: 10.1111/jth.14125. Epub 2018 May 11. J Thromb Haemost. 2018. PMID: 29665242
-
Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.J Thromb Haemost. 2018 Feb;16(2):303-315. doi: 10.1111/jth.13917. Epub 2018 Jan 11. J Thromb Haemost. 2018. PMID: 29197156 Free PMC article.
-
A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.Methods Mol Biol. 2023;2663:569-588. doi: 10.1007/978-1-0716-3175-1_37. Methods Mol Biol. 2023. PMID: 37204737 Review.
-
Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.Int J Mol Sci. 2023 May 11;24(10):8584. doi: 10.3390/ijms24108584. Int J Mol Sci. 2023. PMID: 37239930 Free PMC article. Review.
References
-
- Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens‐Donadel S, van Geet C, Kenet G, Makipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group . Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231–9. - PubMed
-
- Hay CR. Factor VIII inhibitors in mild and moderate‐severity haemophilia A. Haemophilia 1998; 4: 558–63. - PubMed
-
- Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12 (Suppl. 6): 15–22. - PubMed
-
- Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non‐genetic risk factors. Haemophilia 2006; 12 (Suppl. 6): 8–13. - PubMed
-
- Anzengruber J, Lubich C, Prenninger T, Gringeri A, Scheiflinger F, Reipert BM, Malisauskas M. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis‐a‐vis soluble protein aggregates and subvisible particles. J Thromb Haemost 2018; 16: 1176–81. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
